UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions

被引：23

作者：

Harris, Michael ^{[1
]}

Erridge, Simon ^{[1
,2
]}

Ergisi, Mehmet ^{[1
]}

Nimalan, Devaki ^{[1
]}

Kawka, Michal ^{[1
]}

Salazar, Oliver ^{[1
]}

Ali, Rayyan ^{[1
]}

Loupasaki, Katerina ^{[1
]}

Holvey, Carl ^{[2
]}

Coomber, Ross ^{[2
,3
]}

Usmani, Azfer ^{[2
,4
]}

Sajad, Mohammed ^{[2
,5
]}

Hoare, Jonathan ^{[1
,2
]}

Rucker, James J. ^{[2
,6
,7
]}

Platt, Michael ^{[1
,2
]}

Sodergren, Mikael H. ^{[1
,2
]}

机构：

[1] Imperial Coll London, London, England

[2] Sapphire Med Clin, London, England

[3] St Georges Hosp NHS Trust, London, England

[4] Dartford & Gravesham Nhs Trust, Dartford, Kent, England

[5] Dudley Grp Hosp Nhs Trust, Dudley, W Midlands, England

[6] Kings Coll London, Dept Psychol Med, London, England

[7] South London & Maudsley NHS Fdn Trust, London, England

来源：

EXPERT REVIEW OF CLINICAL PHARMACOLOGY | 2022年 / 15卷 / 04期

关键词：

Medical cannabis; chronic pain; pharmacotherapy; pain severity; pain interference; health-related quality of life; opioid dosing; LOW-BACK-PAIN; ANXIETY DISORDER; CB2; RECEPTOR; DOUBLE-BLIND; ASSOCIATION; GABAPENTIN; DEPRESSION;

D O I：

10.1080/17512433.2022.2017771

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objectives To explore pain-specific, general health-related quality of life (HRQoL), and safety outcomes of chronic pain patients prescribed cannabis-based medicinal products (CBMPs). Methods A case series was performed using patients with chronic pain from the UK Medical Cannabis Registry. Primary outcomes were changes in Brief Pain Inventory short-form (BPI), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2), Visual Analogue Scale-Pain (VAS), General Anxiety Disorder-7 (GAD-7), Sleep Quality Scale (SQS), and EQ-5D-5L, at 1, 3, and 6 months from baseline. Statistical significance was defined at p-valueResults 190 patients were included. Median initial Delta(9)-tetrahydrocannabinol and cannabidiol daily doses were 2.0mg (range:0.0-442.0mg) and 20.0mg (range:0.0-188.0mg) respectively. Significant improvements were observed within BPI, SF-MPQ-2, GAD-7, SQS, EQ-5D-5 L index, and VAS measures at all timepoints (p<0.050). Seventy-five adverse events (39.47%) were reported, of which 37 (19.47%) were rated as mild, 23 (12.11%) as moderate, and 14 (7.37%) as severe. Nausea (n=11; 5.8%) was the most frequent adverse event. Conclusion An association was identified between patients with chronic pain prescribed CBMPs and improvements in pain-specific and general HRQoL outcomes. Most adverse events were mild to moderate in severity, indicating CBMPs were well tolerated. Inherent limitations of study design limit its overall applicability.

引用

页码：473 / 485

页数：13

共 79 条

[21] Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies [J].